Close

Ligand Pharma (LGND) Announces Publishing of Results from Phase 1 Trials with LGD-6972 in Type 2 Diabetes Mellitus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/26/2024

1. META
2. CMG
3. LRCX
4. IBM
5. SPY
6. HCP
7. BA
8. SNAP
9. TMUS
10. GOOGL


Go back to Ligand Pharma (LGND) Announces Publishing of Results from Phase 1 Trials with LGD-6972 in Type 2 Diabetes Mellitus
LIGAND PHARMA (NASDAQ: LGND) Delayed: 70.37 -0.63 (0.89%)
Previous Close $71.00    52 Week High $139.79 
Open $70.24    52 Week Low $82.07 
Day High $71.17    P/E 163.65 
Day Low $69.63    EPS $0.43 
Volume 106,715